We are live on ! Find out more

State Street Health Care Select Sector SPDR ETF

XLV

Market cap $44.5B

171.99 USD

+1.18

0.69%

At close Updated Oct 12, 4:00 PM EDT

Pre-market

After hours

172.50

+0.51

0.3%

1 day

0.69%

5 days

2.38%

1 month

2.53%

3 months

6.55%

6 months

16.23%

Year to date

10.6%

1 year

21.16%

5 years

37.22%

10 years

145.49%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 53.6%

Neutral 35.7%

Negative 10.7%

ValuEngine Weekly Commentary: Sector And ETF Performance

U.S. equity markets were mixed this week, with technology and growth-related areas leading, while several defensive and rate-sensitive sectors moved lower. The NASDAQ 100 ETF rose 3.24%, and the S&P 500 ETF gained 1.29%, supported by strong performance in Technology, Communication Services, Health Care, and Industrials.

ValuEngine Weekly Commentary: Sector And ETF Performance

The Motley Fool

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration

XLV offers a significantly lower expense ratio and a higher dividend yield compared to IBB. IBB has delivered higher one-year returns but carries substantially higher volatility and a deeper historical drawdown.

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration

The Motley Fool

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks

The State Street Health Care Select Sector SPDR ETF (XLV) offers significantly lower ownership costs, with an expense ratio of 0.08% compared to 0.58% for the Invesco Pharmaceuticals ETF (PJP). PJP provides concentrated exposure to 28 pharmaceutical stocks, while XLV holds 61 diversified healthcare companies.

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Midterms Won't Settle Washington's Volatility

Political volatility should stay elevated even after Democrats retake the House this November, State Street Investment Management said. Republicans are still expected to hold the Senate, leaving little room for sweeping legislation.

Midterms Won't Settle Washington's Volatility

Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets

With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets.

Heard on the Street: With the Food and Drug Administration's hard-liners gone, investors are rushing back into rare-disease bets

The Motley Fool

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

XLV has a significantly lower expense ratio of 0.08% compared to IXJ's 0.38%. IXJ provides broader exposure with 110 holdings across global markets, while XLV concentrates on 60 domestic S&P 500 stocks.

State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

Zacks Investment Research

Midterm Takes Center Stage: What Does It Mean for Markets & ETFs?

Trump's midterm push, election uncertainty and AI's political scrutiny could shape markets. Explore ETFs positioned for potential sector and post-election gains.

Midterm Takes Center Stage: What Does It Mean for Markets & ETFs?

Blend Innovative Growth & Defense With Healthcare ETFs

All too often, when investors look at the healthcare sector, they mostly see its value for its defensive merits. However, that view may be shortsighted and miss the broader picture in today's market.

Blend Innovative Growth & Defense With Healthcare ETFs

XLE, XLF & XLV Forecast: Energy Eyes Breakout as XLV Slips

XLE eyes fresh highs as oil rises, while XLF consolidates and XLV tests key support after breaking below a major trendline.

XLE, XLF & XLV Forecast: Energy Eyes Breakout as XLV Slips

See News Rankings

Price charts implemented using Lightweight Charts™